Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer

Next Previous
Trial Profile

An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Degarelix; Degarelix; Goserelin; Goserelin; Histrelin; Histrelin; Leuprorelin; Leuprorelin; Triptorelin; Triptorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions

Most Recent Events

  • 11 May 2025 Status changed from active, no longer recruiting to completed.
  • 02 May 2024 Planned End Date changed from 10 Apr 2024 to 10 Apr 2025.
  • 28 Apr 2023 Planned End Date changed from 10 Apr 2023 to 10 Apr 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top